首页> 美国卫生研究院文献>other >The novel POSEIDON stratification of ‘Low prognosis patients in Assisted Reproductive Technology’ and its proposed marker of successful outcome
【2h】

The novel POSEIDON stratification of ‘Low prognosis patients in Assisted Reproductive Technology’ and its proposed marker of successful outcome

机译:辅助生殖技术的低预后患者的新颖POSEIDON分层及其成功预后的标志

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

In reproductive medicine little progress has been achieved regarding the clinical management of patients with a reduced ovarian reserve or poor ovarian response (POR) to stimulation with exogenous gonadotropins -a frustrating experience for clinicians as well as patients. Despite the efforts to optimize the definition of this subgroup of patients, the existing POR criteria unfortunately comprise a heterogeneous population and, importantly, do not offer any recommendations for clinical handling. Recently, the POSEIDON group ( >Patient- >Oriented >Strategies >Encompassing >Individualize >D Oocyte >Number) proposed a new stratification of assisted reproductive technology (ART) in patients with a reduced ovarian reserve or unexpected inappropriate ovarian response to exogenous gonadotropins. In brief, four subgroups have been suggested based on quantitative and qualitative parameters, namely, i. Age and the expected aneuploidy rate; ii. Ovarian biomarkers (i.e. antral follicle count [AFC] and anti-Müllerian hormone [AMH]), and iii. Ovarian response - provided a previous stimulation cycle was performed. The new classification introduces a more nuanced picture of the “low prognosis patient” in ART, using clinically relevant criteria to guide the physician to most optimally manage this group of patients. The POSEIDON group also introduced a new measure for successful ART treatment, namely, the ability to retrieve the number of oocytes needed for the specific patient to obtain at least one euploid embryo for transfer. This feature represents a pragmatic endpoint to clinicians and enables the development of prediction models aiming to reduce the time-to-pregnancy (TTP). Consequently, the POSEIDON stratification should not be applied for retrospective analyses having live birth rate (LBR) as endpoint. Such an approach would fail as the attribution of patients to each Poseidon group is related to specific requirements and could only be made prospectively. On the other hand, any prospective approach (i.e. RCT) should be performed separately in each specific group.
机译:在生殖医学中,对于卵巢储备减少或卵巢对外源促性腺激素刺激的不良反应(POR)较差的患者,其临床治疗进展甚微,这对临床医生和患者而言都是令人沮丧的经历。尽管努力优化该患者亚组的定义,但是现有的POR标准不幸地包含了异质人群,重要的是,没有为临床处理提供任何建议。最近,POSEIDON小组(> P 态度-> O 面向> S 策略> E 包含了> I 将个体化的> DO 细胞> N (琥珀色)建议对卵巢储备减少或卵巢对外源促性腺激素的意外不良反应的患者进行辅助生殖技术(ART)的新分层。简而言之,根据定量和定性参数,提出了四个亚组,即i。年龄和预期的非整倍性率; ii。卵巢生物标志物(即,卵泡计数[AFC]和抗苗勒管激素[AMH]),以及iii。卵巢反应-提供先前的刺激周期。新分类使用临床相关标准指导医师最优化地管理这组患者,从而为ART中的“低预后患者”提供了更为细微的描述。 POSEIDON小组还介绍了一项成功进行ART治疗的新措施,即能够检索特定患者获得至少一个整倍体胚胎进行移植所需的卵母细胞数量。此功能代表了临床医生务实的终点,并能够开发旨在减少怀孕时间(TTP)的预测模型。因此,不应将POSEIDON分层应用于以活产率(LBR)为终点的回顾性分析。由于患者对每个波塞冬组的归因与具体要求有关,因此只能以前瞻性方式进行,因此这种方法将失败。另一方面,任何预期方法(即RCT)都应在每个特定组中分别执行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号